Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of PF-06651600 in Healthy Subjects
NCT02684760Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ritlecitinib tosilate in inflammatory bowel disease (IBD) (6 cohorts), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time, Area Under the Curve From Time Zero to Last Quantifiable Concentration and 1 more. Started Feb 2016; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02684760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684760.